arrow
Y

Yeow Tee Goh

Department of Haematology
H指数:27
被引数:3,869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results

Asciminib单药治疗BCR::ABL1 T315I突变慢性期慢性粒细胞白血病:1期试验最终结果

Leukemia
IF13.4
2026-07-160
OAAI
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in ASC4FIRST

Asciminib在asc4首先在新诊断的慢性粒细胞白血病中表现出优异的疗效和安全性

Blood
IF23.1
2025-12-170
OAAI
Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore

供者肾移植在移植前患有血液系统恶性肿瘤的候选者中的应用:新加坡的文献综述及受者分配方案

2025-08-220
OAAI
A formula using day 4 parameters to predict next-day peripheral blood stem cell yield in healthy haematopoietic stem cell donors

使用第4天参数预测健康造血干细胞捐献者次日外周血干细胞产量的公式

2025-02-030
PRE
Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore
2024-12-270
PRE
Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab- Real-World Retrospective Study

结外滤泡性淋巴瘤的结局受诱导化疗免疫疗法选择及维持性利妥昔单抗的影响——真实世界回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

在酪氨酸激酶抑制剂治疗 ≥ 1个T315I突变的慢性期慢性粒细胞白血病患者中单药治疗: 2年随访结果

LEUKEMIA
IF13.4
2024-05-168
OAAI
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)

在亚太地区建立多发性骨髓瘤临床注册: 亚太骨髓瘤及相关疾病注册中心 (APAC MRDR)

2024-05-020
OAAI
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
2023-09-0116
PRE
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Asciminib单药治疗无BCR的cml-cp患者::ABL1 T315I突变与至少两个先前的TKIs治疗: 4年1期安全性和有效性结果

LEUKEMIA
IF13.4
2023-03-2223
OAAI
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
LANCET
IF88.5
2023-01-01102
PRE
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
2021-10-169
OAAI